Newsbenzinga
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue
· Published
Article summary
Supernus and Indivior agree to merge in an all-stock deal, targeting $2.2 billion in revenue and $125 million in synergies.
An excerpt from the original article.
Comments —
Loading comments…